McDonnell delights extensively in financial and strategic operations, and revels in the leading global group station of a wide variety of sectors. During his tenure at IQVIA, the apple has become an undisputed leader in the use of knowledge and result generation for patients.
McDonnell succeeds Jeffrey Capello, who has served as Biogen’s executive vice president and leading economic officer since December 2017. Capello resigned as CFO following McDonnell’s appointment on August 15, 2020, and was responsible for the apple until September 15, 2020, to lend a hand in the transition.
“I am very happy to welcome Mike to Biogen at this exciting time, when we have been given so many prospective breakout remedies in our portfolio. Mike revels in and realizes achievements, adding his extensive experience in creating strategic economic positions and considerations. make it suitable for Biogen at this point in our history,” said Michel Vounatsos, CEO. “I want to thank Jeff for his great apple contributions to Biogen and we are pleased that Jeff will continue for a while to make an elegant transition. We wish him all the best.”
Biogen will release the effects of a quarter of 2020 on July 22, 2020.
About Michael (Mike) McDonnell
Mike McDonnell, five years and six, was executive vice president and chief financial officer of IQVIA Holdings Inc., a leading global provider of complex analytics, generation responses, and contract studies for the life sciences industry, from December 201 to July 2020. Prior to that, McDonnell was Executive Vice President and Chief Financial Officer of Intelsat, a leading global satellite company from November 2008 to December 2001, as Executive Vice President and Chief Financial Officer of MCG Capital Corporation, a public finance company, from September 200 to October 2008 and as Chief Executive Officer of MCG Capital Corporation from August 2006 to October 2008. Prior to joining MCG Capital Corporation, McDonnell served as Executive Vice President and Chief Financial Officer of EchoStar Communications Corporation (f/k/a DISH Netpaintings Corporation), a direct service to satellite television operator, from July 2004 to August 200 and as senior vice president and Chief Financial Officer from August 2000 to July 2004. McDonnell spent 1 year at PricewaterhouseCoopers LLP, adding four years as a partner. He holds a bachelor’s degree in accounting science from Georgethe City University and is a public accountant.
About Biogen
We publish data that is also critical to investors on our website on www.biogen.com. Follow us on social networks: Twitter, LinkedIn, Facebook, YouTube.
Safe Harbor through Biogen
This press release includes forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, adding statements of our business activities; Our strategy and plans The perspective of our business activities and piping systems; Risks and mismatches applicable with the design and marketing of drugs; Our long-term economic and scoring effects; and the expected benefits of appointing McDonnell as Executive Vice President and Chief Financial Officer. These forward-looking statements may be accompanied by words such as “objective,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “anticipate,” “target,” “pretend,” “could, “”plan”, “prospective”, “possible”, “will”,” “and other words and terms of similar meaning. The progression and marketing of medicines carries a degree of risk h8, and only a small variety of studies and progression systems cause the commercialization of a product. The outcome of the initial clinical trials may not be indicative of the full effects or outcome of subsequent or larger-scale clinical trials, and may not be fully approved. You do not unduly rely on such statements.
These statements involve threats and uncertainties that may also have genuine effects to differentiate the most important friends from those reflected in those statements, adding, but not limited to: controlling threats and the primary framework of staff replenishments; our reliance on sales of our products The inability to provide direct protection and enforce our knowledge, high-value assets and other asset rights and applicable threats and uncertainties with high-value asset claims and challenges; the direct and indirect effects of COVID-1’s continuous pandemic on our operations, results of operations and fiscal position; Uncertainty about the wise long-term interpretation of the development, licensing or acquisition of other candidate products or additional indications for existing products; The inability to compete well due to the critical product festival in our product markets; The inability of wise men to execute a great friend to execute or authenticate the expected benefits of our strategic and expansion initiatives; the threat that leclassified positive ads for a clinical trial will never be better repeated in subsequent or confirmation trials, or that prudence in early clinical trials does not expect the outcome of large-scale or subsequent clinical trials in other prospective studies indications The applicable threats with clinical trials, which add our ability to properly manage clinical activities , unforeseen considerations that would oppose additional knowledge or analysis received during clinical trials, the regulatory government may require additional data or additional studies, or may not delay or delay approval of our drug candidates; and the occurrence of complicated defense events, usage restrictions with our products or product liability claims. This describes Apple’s main but not all points, which can also cause genuine effects to differ from our expectations in an advanced Apple search statement. Investors deserve to take this precaution into account, in addition to the threat points known in our latest annual or quarterly report and other reports that have been submitted to us by the Securities and Exhibition Commission. These statements are based on our current ideals and expectations and only refer to the date of this press release. We assume that it is not mandatory to publicly update direct search statements, whether due to current data, long-term progress or other.